A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Tanabe Pharma America, Inc.
- Study ID
- NCT06943521
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Biliary Tract Cancer
- Breast Cancer
- Cervical Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gastric Cancer
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Neuroendocrine Carcinoma (NEC)
- Neuroendocrine Tumor (NET)
- Non-small Cell Lung Cancer (NSCLC)
- Nuclear Protein in Testis (NUT) Carcinoma
- Ovarian Cancer
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Prostate Cancer
- Soft Tissue Sarcoma
- Urothelial Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- MT-4561 — DRUGi.v.
Study Details
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerability, PK and pharmacodynamics of MT-4561 and determining the Maximum Tolerated Dose (MTD) using the Bayesian Optimal Interval (BOIN) design. The study details and doses of Part 2 (dose-optimization) and Part 3 (Drug-Drug Interaction) will be available after review of applicable Part 1 results.
Key Dates
- First listed
- Apr 24, 2025
- Start date
- Apr 18, 2025
- Status verified
- Dec 2025
- Primary completion
- Aug 31, 2028
- Completion
- Aug 31, 2028
Study Design
- Enrollment
- 27 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Part 1 (Dose-escalation)Intravenous (IV) infusion of MT-4561 once every week in 28-day cycle, until disease progression or discontinuation criteria are met.
Primary Outcome Measure
Incidence of Adverse Event, Dose limiting toxicities (DLTs) [ Time Frame: a 28-day cycle ]
Central Contacts
- Clinical Trials Information Desk, to prevent miscommunication,Please E-mail
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Southern California | Los Angeles | California | 90033 | - |
| START Midwest | Grand Rapids | Michigan | 49546 | - |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | - |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | - |
Find similar trials in Los Angeles, CA
Nationwide
Breast cancer trialsCervical cancer trialsEndometrial cancer trialsEsophageal cancer trialsGastric cancer trialsOvarian cancer trialsProstate cancer trialsBladder cancer trialsOncology trialsBreast oncology trialsWomen's health trialsGynecologic oncology trialsGI oncology trialsProstate oncology trialsMen's health trialsUrology trials
By condition
By specialty
Related Studies
- Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenRecruiting · M.D. Anderson Cancer Center · Miami, Florida
- Active Surveillance for Cancer of the Prostate (ASCaP)Recruiting · Jonsson Comprehensive Cancer Center · Los Angeles, California
- Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical ProstatectomyRecruiting · Proton Collaborative Group · Little Rock, Arkansas
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood SamplesRecruiting · Stanford University · Stanford, California